14 October 2020 : Laboratory Research
High Expression of MUC15 Is Correlated with Poor Prognosis of Pancreatic Cancer and Promotes Migration, Invasion, and Chemo-Resistance In Vitro
Shunda Wang1ABCDEF, Junjie Li2ABD, Lei You1AEF, Menghua Dai1ACEG*, Yupei Zhao1AEGDOI: 10.12659/MSM.926432
Med Sci Monit 2020; 26:e926432
Table 2 Relationship between membrane MUC15 expression and clinicopathological characteristics in pancreatic cancer.
| Variables | n | MUC15 expression | P-value | |
|---|---|---|---|---|
| High | Low | |||
| 0.728 | ||||
| Male | 26 | 10 (38.5%) | 16 (61.5%) | |
| Female | 11 | 5 (45.5%) | 6 (54.5%) | |
| 0.842 | ||||
| ≤60 | 19 | 8 (42.1%) | 11 (57.9%) | |
| >60 | 18 | 7 (38.9%) | 11 (61.1%) | |
| 0.283 | ||||
| Elevated | 24 | 8 (33.3%) | 16 (66.7%) | |
| Normal | 11 | 6 (54.5%) | 5 (45.5%) | |
| 0.265 | ||||
| ≥4cm | 13 | 7 (53.8%) | 6 (46.2%) | |
| <4cm | 23 | 8 (34.8%) | 15 (65.2%) | |
| 0.391 | ||||
| Head | 21 | 10 (47.6%) | 11 (52.4%) | |
| Non-head | 15 | 5 (33.3%) | 10 (66.7%) | |
| 0.669 | ||||
| Well-moderate | 28 | 11 (39.3%) | 17 (60.7%) | |
| Poor | 5 | 2 (40.0%) | 3 (60.0%) | |
| 0.681 | ||||
| Absent | 13 | 6 (46.2%) | 7 (53.8%) | |
| Present | 23 | 9 (39.1%) | 14 (60.9%) | |
| 0.602 | ||||
| Absent | 26 | 11 (42.3%) | 15 (57.7%) | |
| Present | 10 | 4 (40.0%) | 6 (60.0%) | |
| 0.486 | ||||
| Absent | 20 | 9 (45.0%) | 11 (55.0%) | |
| Present | 15 | 5 (33.3%) | 10 (66.7%) | |
| 0.955 | ||||
| I–IIa | 19 | 8 (42.1%) | 11 (57.9%) | |
| ≥IIb | 17 | 7 (41.2%) | 10 (58.8%) | |
| 0.681 | ||||
| T1–2 | 13 | 6 (46.2%) | 7 (53.8%) | |
| >T3 | 23 | 9 (39.1%) | 14 (60.9%) | |
| 0.650 | ||||
| N0 | 20 | 9 (48.0%) | 11 (52.0%) | |
| N1 | 16 | 6 (37.5%) | 10 (62.5%) | |
| Total patient number does not equal 37 in all categories, as patient information was not available for all cases. T – tumor; N – lymph node. | ||||